SEOUL, February 05 (AJP) - South Korean biopharmaceutical company Celltrion reported record annual earnings on Thursday as strong sales of newer, higher-margin biosimilars lifted both revenue and profitability.
In a regulatory filing, the firm said consolidated revenue for 2025 rose 17 percent from a year earlier to 4.16 trillion won, while operating profit jumped 137.5 percent to 1.17trillion won. It marked the first time Celltrion surpassed both 4 trillion won in annual revenue and 1 trillion won in operating profit in the same year.
Operating margin rose to 28.1 percent, up 14.3 percentage points from a year earlier.
Fourth-quarter revenue climbed 25.1 percent year on year to 1.33 trillion won, while operating profit surged 142 percent to 475.2 billion won, exceeding company guidance.
Celltrion attributed the growth largely to rapid expansion of higher-margin new biosimilars. Alongside steady sales of established products such as Remsima, Truxima and Herzuma, newer drugs including Remsima SC, Yuflyma, Vegzelma and Zymfentra gained traction, lifting global biopharmaceutical sales 24 percent to 3.9 trillion won.
New products accounted for 54 percent of total biopharmaceutical sales, the company said.
Celltrion set a 2026 revenue target of 5.3 trillion won and plans to increase the share of new products in sales to 70 percent through bidding strategies centered on newer drugs and by strengthening its direct sales network.
The company also plans to expand its contract manufacturing and development businesses through its Branchburg, New Jersey, facility, while broadening its biosimilar and innovative drug pipeline to support longer-term growth.
* This article, published by Aju Business Daily, was translated by AI and edited by AJP.
Copyright ⓒ Aju Press All rights reserved.
